Mometasone furoate in the management of asthma: a review
Authors:
Open Access
- 1 December 2008
- journal article
- review article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 4 (6) , 1201-1208
Abstract
Mometasone furoate in the management of asthma: a review Ricardo A Tan1, Jonathan Corren21California Allergy and Asthma Medical Group, Los Angeles, CA; 2Allergy Research Foundation, Los Angeles, CA, USA Inhaled corticosteroids (ICS) have proven to be the most effective and essential therapy for the treatment of bronchial asthma. The 2007 National Asthma Education and Prevention Program guidelines recommend ICS as preferred therapy for patients with mild to severe persistent asthma. Mometasone furoate (MF) is a relatively new ICS agent with high affinity for the glucocorticoid receptor. It is approved in the US for maintenance treatment of asthma for patients 4 years of age and older. It has been shown to be well tolerated with no significant adverse side effects observed in clinical trials and post-marketing surveillance. The efficacy of mometasone furoate has been established in large, well-designed studies. In patients with persistent asthma previously treated either with short-acting beta-agonists alone or twice-daily maintenance therapy with ICS, once-daily MF has been shown to be superior to placebo in improving lung function, symptom control, and quality of life; and has shown comparable efficacy compared with budesonide, beclomethasone, and fluticasone. Twice-daily dosing with MF has been demonstrated to successfully allow for reduction or elimination of oral corticosteroids in severe asthmatics.Keywords: inhaled steroids, mometasone furoate, once-daily dosing, asthma, stepwise approachKeywords
This publication has 32 references indexed in Scilit:
- Comparison of Mometasone Furoate Dry Powder Inhaler and Fluticasone Propionate Dry Powder Inhaler in Patients with Moderate to Severe Persistent Asthma Requiring High-Dose Inhaled Corticosteroid Therapy: Findings from a Noninferiority TrialJournal of Asthma, 2008
- Inhaled Corticosteroids in Children with AsthmaPediatric Drugs, 2007
- Once-daily evening administration of mometasone furoate in asthma treatment initiationAnnals of Allergy, Asthma & Immunology, 2006
- METABOLISM OF MOMETASONE FUROATE AND BIOLOGICAL ACTIVITY OF THE METABOLITESDrug Metabolism and Disposition, 2006
- Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroidsCurrent Medical Research and Opinion, 2005
- Mometasone furoate degradation and metabolism in human biological fluids and tissuesBiopharmaceutics & Drug Disposition, 2003
- A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoateClinical Therapeutics, 2001
- Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparatorAnnals of Allergy, Asthma & Immunology, 2001
- Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionateAnnals of Allergy, Asthma & Immunology, 2001
- Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhalerAnnals of Allergy, Asthma & Immunology, 2001